JUROX OVARID TABLETS
Flammability | 0 | |
Toxicity | 0 | |
Body Contact | 0 | |
Reactivity | 1 | |
Chronic | 3 | |
SCALE: Min/Nil=0 Low=1 Moderate=2 High=3 Extreme=4 |
Tablets for the prevention or postponement of oestrus in dogs and cats, treatment of
miliary eczema and rodent ulcer in cats, oestrogen- dependent mammary tumors in bitches
and behavioural abnormalities in dogs and cats.
Limited evidence of a carcinogenic effect.
May cause harm to breastfed babies.
The material has NOT been classified as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g. liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality (death) rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, unintentional ingestion is not thought to be cause for concern.
Although the material is not thought to be an irritant, direct contact with the eye may produce transient discomfort characterized by tearing or conjunctival redness (as with windburn).
The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting. Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.
The material is not thought to produce adverse health effects or irritation of the respiratory tract (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.
There has been concern that this material can cause cancer or mutations, but there is not enough data to make an assessment.
There is some evidence that human exposure to the material may result in developmental toxicity. This evidence is based on animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects. Exposure to the material for prolonged periods may cause physical defects in the developing embryo (teratogenesis). Progestogens cause gastrointestinal disturbances, acne, swelling, weight gain, skin rashes, hives, menal depression, breast changes with discomfort and occasionally enlargement in males, changes in sex drive, altered menstrual cycles or irregular menstrual bleeding. Liver abnormalities and jaundice have been reported. Some progestogens have been associated with an increase in congenital abnormalities. Repeated intake of progesterones may produce headache, nausea, vomiting, diarrhea, inflammation of the mouth cavity with ulcers, swelling, weight change, fever, fatigue, increased or decreased sleep, mental depression, allergic rashes including hives and itching, acne, sensitivity to light, pigmented skin, hair loss, excessive hair growth, clotting and vein inflammation, obstructive jaundice, and precipitation of porphyria. Other symptoms may include menstrual disorders, breast changes, effects on the cervix, Candida infections of the vagina, decreased sex drive, and inhibition of sperm production. Exposure during the first trimester may produce mild masculinization of the external genitalia of the female fetus or defects in the male. Exposure to female sex hormones during the first trimester has also been associated with various birth defects of the cardiovascular system and bones.